Benjamin F. Edwards & Company’s CollPlant Biotechnologies CLGN Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2024
Q2
$197K Sell
3,976
-1,069
-21% -$59.3K ﹤0.01% 913
2024
Q1
$272K Buy
5,045
+30
+0.6% +$1.62K ﹤0.01% 820
2023
Q4
$320K Buy
5,015
+510
+11% +$27.9K 0.01% 733
2023
Q3
$254K Sell
4,505
-416
-8% -$27.5K 0.01% 670
2023
Q2
$399K Sell
4,921
-1,670
-25% -$122K 0.02% 567
2023
Q1
$463K Buy
6,591
+486
+8% +$47.7K 0.02% 503
2022
Q4
$510K Sell
6,105
-436
-7% -$29.8K 0.02% 462
2022
Q3
$447K Sell
6,541
-640
-9% -$51.9K 0.02% 459
2022
Q2
$585K Sell
7,181
-346
-5% -$31.8K 0.03% 419
2022
Q1
$861K Buy
7,527
+1,658
+28% +$182K 0.04% 368
2021
Q4
$960K Buy
5,869
+105
+2% +$18.7K 0.04% 351
2021
Q3
$973K Sell
5,764
-699
-11% -$126K 0.05% 345
2021
Q2
$1.37M Sell
6,463
-519
-7% -$82.9K 0.07% 282
2021
Q1
$938K Buy
6,982
+5,530
+381% +$834K 0.05% 343
2020
Q4
$156K Buy
+1,452
New +$117K 0.01% 702

Other funds holding CLGN

Benjamin F. Edwards & Company's CLGN Position: Q2 2024 in Review

Benjamin F. Edwards & Company reduced its CollPlant Biotechnologies (CLGN) stake by 21% in Q2 2024, selling an estimated $59.3K and leaving 3,976 shares worth $197K. The position accounts for ﹤0.01% of the portfolio, ranked #913.

Benjamin F. Edwards & Company first reported a position in CLGN in Q4 2020 and has held it in 15 quarters since. The position peaked at $1.37M in Q2 2021. 14 funds tracked by Wall St. Rank hold CLGN as of Q2 2024.

  • Benjamin F. Edwards & Company held 3,976 shares of CollPlant Biotechnologies worth $197K as of Q2 2024.
  • Benjamin F. Edwards & Company sold 1,069 CollPlant Biotechnologies shares in Q2 2024, an estimated $59.3K.
  • CollPlant Biotechnologies made up ﹤0.01% of Benjamin F. Edwards & Company's portfolio in Q2 2024, its #913 holding.
  • Benjamin F. Edwards & Company first reported a position in CollPlant Biotechnologies in Q4 2020 and has held it in 15 quarters since.
  • Benjamin F. Edwards & Company's CollPlant Biotechnologies position peaked at $1.37M in Q2 2021.
  • 14 funds tracked by Wall St. Rank held CollPlant Biotechnologies as of Q2 2024.

Based on Benjamin F. Edwards & Company's 13F filing for Q2 2024, filed 12 Aug 2024.